TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. (RNAZ) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · RNAZ · as of Jun 9, 2026
Key Statistics
Explore TransCode Therapeutics, Inc. Data
rnaz stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
Competitors & Peers
rnaz competitorsRNAZ
ACXP
APRE
APVO
BOLT
GLTOStock Performance
Full HistoryAbout TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease.…
what is transcode therapeutics, inc. · rnaz stock overview · transcode therapeutics, inc. company profile · who is transcode therapeutics, inc. ceo · rnaz NASDAQ · transcode therapeutics, inc. headquarters · transcode therapeutics, inc. business segments
About Stock Overview & Key Data
TransCode Therapeutics, Inc. (RNAZ) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 8, 2021. As of the latest trading session, RNAZ stock price is $5.09, with a market capitalization of $4.8M. The stock has returned -32.13% over the past 12 months and -25.48% year-to-date.
According to 1 Wall Street analysts, the consensus rating for TransCode Therapeutics, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, TransCode Therapeutics, Inc. reported revenue of — and net income of -$34.7M. For detailed data — including TransCode Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, TransCode Therapeutics, Inc. (RNAZ) stock price is $5.09. The stock is traded on NASDAQ under the ticker symbol RNAZ. The 52-week range is $3.82 – $20.99.